‘Omics’ Big Data and Precision Medicine

Jian GuanOpenalex Unknown 2025 · DOI · OpenAlex

Abstract

Omics Big Data underpins genetic information and its expression for precision medicine, thereby accelerating the discovery of disease mechanisms, drug targets, and drug development. It has a wide range of applications, including clinical genomics and pharmacogenomics. This paper offers a concise overview of various types of omics, current trends, and characteristics of the resulting omics big data. It also explores the applications of these data in the context of rare diseases, tumors, chronic diseases, and infectious diseases, along with the challenges of data sharing. The discussion primarily focuses on analyzing the ethical issues and challenges in clinical genomics and proposing ethical guidelines for clinical genomic testing and interpretation.

Introduction

The landscape of modern healthcare is undergoing a fundamental transformation driven by "Omics" big data—the massive datasets generated from studying genomes, proteomes, and metabolomes. This shift marks a transition from traditional symptom-based diagnosis to data-driven, personalized precision medicine. By integrating high-dimensional molecular data with clinical phenotypes, researchers and clinicians can now tailor treatments to an individual's specific molecular profile, moving away from the "one-size-fits-all" approach.

The Precision Medicine Paradigm Shift

Precision medicine aims to flip the traditional medical script. A key innovation highlighted in recent research is the "Reverse Phenotype" shift. Traditionally, medical research moves from observable symptoms (phenotype) to identifying genetic causes (genotype). However, a promising trend toward "Genotype-first" diagnostics is emerging, where participants are selected based on specific genomic variants to discover previously unforeseen clinical traits.

This evolution requires a bridge between Physiomics (the study of integrated physiological networks) and Phenomics (the systematic study of phenotypes on a genome-wide scale). Precision medicine relies on this integration to treat the organism as a coordinated entity rather than a collection of isolated data points, a concept known as "Systemic Omics."

Methodological Framework and Data Integration

The implementation of precision medicine relies on a suite of high-throughput technologies and analytical frameworks:

  • Data Acquisition: Foundational tools include Next-Generation Sequencing (NGS), Whole-Exome Sequencing (WES), and Liquid Chromatography-Mass Spectrometry (LC-MS/MS).
  • Single-Cell Multi-Omics: This trending approach measures multiple data types within the same cell to capture spatial and temporal complexity.
  • AI and Machine Learning: Deep Learning is the primary tool for handling the "small $n$, large $p$" problem—where datasets have relatively few patient samples ($n$) but a massive number of variables ($p$). These models are essential for integrating disparate omics layers, such as transcriptomics and proteomics.
  • Value Grading System: To ensure clinical utility, a three-level hierarchy for clinical genetic data is proposed. Level 1 data is already integrated into clinical guidelines, while Level 3 remains based on preliminary literature.

Clinical Impact and Key Results

The integration of omics data has already yielded significant clinical results across various disease categories:

  • Rare Disease Diagnostics: Genomics has achieved diagnostic rates of 20–30% for rare diseases, significantly outperforming traditional diagnostic methods.
  • Cancer Genomics: Data from the 100,000 Genomes Project (UK) revealed small minor variants in 94% of glioblastoma cases and actionable structural variants in 13% of sarcomas, demonstrating the high clinical utility of Whole Genome Sequencing (WGS).
  • Metabolomics: Current non-targeted tests using LC-MS can now detect over 4,000 mass spectrometry peaks, providing a high-resolution snapshot of a patient's metabolic state.

Ethical and Technical Challenges

Despite technological maturity, several hurdles remain for the widespread implementation of clinical genomics:

  1. The Fragility of Anonymity: Genomic data is inherently identifiable. Because a person's genetic code is their ultimate "fingerprint," standard de-identification techniques are often insufficient, making data sharing a complex legal and ethical issue.
  2. The "Right Not to Know": In the era of incidental findings—where testing reveals risks for diseases unrelated to the original clinical question—patient autonomy is paramount. Ethical guidelines must protect a patient's right to decline certain genetic information.
  3. The Treatment Gap: A recurring limitation is the ability to identify a pathogenic gene without having an effective intervention, which can lead to patient anxiety.
  4. Informatics Noise: Integrating heterogeneous data from different platforms introduces significant "noise," requiring more robust normalization and scaling techniques in machine learning models.

Conclusion

Omics big data is the engine of precision medicine, offering unprecedented insights into disease mechanisms and drug targets. While technical challenges regarding data storage and standardization persist, the primary focus must remain on establishing robust ethical frameworks and clinical guidelines. As the field moves toward systemic omics, the goal remains a healthcare system that is truly personalized, predictive, and preventative.

Summary updated

Abstract

Omics Big Data underpins genetic information and its expression for precision medicine, thereby accelerating the discovery of disease mechanisms, drug targets, and drug development. It has a wide range of applications, including clinical genomics and pharmacogenomics. This chapter offers a concise overview of various types of omics, current trends, and characteristics of the resulting omics big data. It also explores the applications of these data in the context of rare diseases, tumors, chronic diseases, and infectious diseases, along with the challenges of data sharing. The discussion primarily focuses on analyzing the ethical issues and challenges in clinical genomics and proposing ethical guidelines for clinical genomic testing and interpretation. These guidelines were published as an expert consensus.
BibTeX
@inproceedings{guan2025omics,
  author = {Jian Guan},
  title = {{‘Omics’ Big Data and Precision Medicine}},
  booktitle = {Openalex Unknown},
  year = {2025},
  doi = {10.1007/978-981-95-2806-6\_12},
}
Figure